Cormorant Asset Management Has Trimmed Coherus Biosciences (CHRS) Holding; Wayne Savings Bancshares (WAYN)’s Sentiment Is 0.67

August 10, 2017 - By Peter Erickson

Cormorant Asset Management Llc decreased Coherus Biosciences Inc (CHRS) stake by 9.9% reported in 2016Q4 SEC filing. Cormorant Asset Management Llc sold 57,016 shares as Coherus Biosciences Inc (CHRS)’s stock declined 0.89%. The Cormorant Asset Management Llc holds 519,090 shares with $14.61 million value, down from 576,106 last quarter. Coherus Biosciences Inc now has $626.43M valuation. The stock declined 3.17% or $0.4 reaching $12.2 per share. About 118,244 shares traded. Coherus Biosciences Inc (NASDAQ:CHRS) has risen 17.62% since August 10, 2016 and is uptrending. It has outperformed by 0.92% the S&P500.

Wayne Savings Bancshares, Inc. is the unitary thrift holding firm for Wayne Savings Community Bank . The company has market cap of $47.49 million. The Bank is a community-oriented institution, which offers a range of consumer and business financial services. It has a 21.55 P/E ratio. The Bank’s primary lending and deposit gathering area includes Wayne, Holmes, Ashland, Medina and Stark counties, where it operates over 10 offices.

Investors sentiment decreased to 1.27 in 2016 Q4. Its down 1.25, from 2.52 in 2016Q3. It dived, as 17 investors sold CHRS shares while 34 reduced holdings. 27 funds opened positions while 38 raised stakes. 29.19 million shares or 6.12% more from 27.50 million shares in 2016Q3 were reported. Bnp Paribas Arbitrage Sa invested 0% of its portfolio in Coherus Biosciences Inc (NASDAQ:CHRS). Nationwide Fund Advisors, Pennsylvania-based fund reported 33,561 shares. Macquarie Group Incorporated Ltd reported 42,555 shares. Moreover, Amer Intl Group Incorporated has 0% invested in Coherus Biosciences Inc (NASDAQ:CHRS). Blackrock Inv Limited Liability Co invested in 0% or 115,414 shares. Blackrock Group holds 0% of its portfolio in Coherus Biosciences Inc (NASDAQ:CHRS) for 11,927 shares. Susquehanna International Grp Inc Inc Ltd Liability Partnership reported 0% of its portfolio in Coherus Biosciences Inc (NASDAQ:CHRS). Spark Mngmt stated it has 0.05% in Coherus Biosciences Inc (NASDAQ:CHRS). Credit Suisse Ag accumulated 142,155 shares or 0% of the stock. Axa reported 309,733 shares stake. Blackrock Institutional Trust Na reported 740,118 shares. Globeflex Capital LP has invested 0.12% of its portfolio in Coherus Biosciences Inc (NASDAQ:CHRS). Carlson Cap LP reported 0.14% in Coherus Biosciences Inc (NASDAQ:CHRS). 22,618 are held by Wells Fargo And Mn. Creative Planning holds 0% or 1,097 shares.

Among 10 analysts covering Coherus Biosciences (NASDAQ:CHRS), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. Coherus Biosciences had 15 analyst reports since September 3, 2015 according to SRatingsIntel. On Monday, November 23 the stock rating was initiated by Barclays Capital with “Overweight”. Robert W. Baird initiated the stock with “Outperform” rating in Wednesday, October 19 report. The stock has “Outperform” rating by Credit Suisse on Wednesday, January 20. The stock of Coherus Biosciences Inc (NASDAQ:CHRS) earned “Buy” rating by Maxim Group on Monday, June 12. The stock has “Buy” rating by Cowen & Co on Monday, June 12. The rating was initiated by Maxim Group on Wednesday, September 7 with “Buy”. The stock of Coherus Biosciences Inc (NASDAQ:CHRS) has “Hold” rating given on Thursday, September 3 by Zacks. The rating was initiated by Citigroup with “Buy” on Wednesday, July 27.

Cormorant Asset Management Llc increased Aclaris Therapeutics Inc stake by 75,000 shares to 976,286 valued at $26.50M in 2016Q4. It also upped Ascendis Pharma A S stake by 100,000 shares and now owns 162,254 shares. Corbus Pharmaceuticals Hldgs was raised too.

It is down 39.43% since August 10, 2016 and is uptrending. It has outperformed by 22.73% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com